Section I: Integrating laboratory medicine with tissue specimens

Current Problems in Cancer

Volumn 38, Issue 5, 2014, Pages 144-158

  Fisher, Kevin E ^a   Smith, Geoffrey H ^a   Neill, Stewart G ^a   Rossi, Michael R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACID; TUMOR MARKER;

ARTICLE; DNA EXTRACTION; HISTOPATHOLOGY; HUMAN; LABORATORY; LABORATORY MEDICINE; MEDICINE; MOLECULAR PATHOLOGY; PATHOLOGIST; QUALITY CONTROL; TISSUES; DIAGNOSTIC PROCEDURE; GENETIC PROCEDURES; GENETICS; INTEGRATED HEALTH CARE SYSTEM; NEOPLASMS; PROCEDURES; STANDARDS;

CLINICAL LABORATORY TECHNIQUES; DELIVERY OF HEALTH CARE, INTEGRATED; GENETIC TECHNIQUES; HUMANS; NEOPLASMS; QUALITY CONTROL; TUMOR MARKERS, BIOLOGICAL;

EID: 84909598966     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2014.08.004     Document Type: Article

References (59)

1. Wians F.H. Clinical laboratory tests: which, why, and what do the results mean?. Lab Med 2009, 40(2):105-113.
2. Grizzle W.E., Bell W.C., Sexton K.C. Issues in collecting, processing and storing human tissues and associated information to support biomedical research. Cancer Biomark 2010, 9(1-6):531-549.
3. Fairley J.A., Gilmour K., Walsh K. Making the most of pathological specimens: molecular diagnosis in formalin-fixed, paraffin embedded tissue. Curr Drug Targets 2012, 13(12):1475-1487.
4. Campos P.F., Gilbert T.M. DNA extraction from formalin-fixed material. Methods Mol Biol 2012, 840:81-85.
5. Walter R.F., Mairinger F.D., Wohlschlaeger J., et al. FFPE tissue as a feasible source for gene expression analysis-a comparison of three reference genes and one tumor marker. Pathol Res Pract 2013, 209(12):784-789.
6. Srinivasan M., Sedmak D., Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 2002, 161(6):1961-1971.
7. Beutler E., Gelbart T., Kuhl W. Interference of heparin with the polymerase chain reaction. Biotechniques 1990, 9(2):166.
8. Spruessel A., Steimann G., Jung M., et al. Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision. Biotechniques 2004, 36(6):1030-1037.
9. Liu M.L., Jeong J., Ambannavar R., et al. Rt-PCR gene expression profiling of RNA from paraffin-embedded tissues prepared using a range of different fixatives and conditions. Methods Mol Biol 2011, 724:205-237.
10. Lawson M.H., Rassl D.M., Cummings N.M., et al. Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA. J Thorac Oncol 2010, 5(7):956-963.
11. Kotorashvili A., Ramnauth A., Liu C., et al. Effective DNA/RNA co-extraction for analysis of microRNAs, mRNAs, and genomic DNA from formalin-fixed paraffin-embedded specimens. PLoS One 2012, 7(4):e34683.
12. Abdueva D., Wing M., Schaub B., Triche T., Davicioni E. Quantitative expression profiling in formalin-fixed paraffin-embedded samples by affymetrix microarrays. J Mol Diagn 2010, 12(4):409-417.
13. Tsiatis A.C., Norris-Kirby A., Rich R.G., et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 2010, 12(4):425-432.
14. Spencer D.H., Tyagi M., Vallania F., et al. Performance of common analysis methods for detecting low-frequency single nucleotide variants in targeted next-generation sequence data. J Mol Diagn 2014, 16(1):75-88.
15. Engelhardt B., Ransohoff R.M. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 2005, 26(9):485-495.
16. Sirota R.L. Defining error in anatomic pathology. Arch Pathol Lab Med 2006, 130(5):604-606.
17. Leiva I.M., Emmert-Buck M.R., Gillespie J.W. Handling of clinical tissue specimens for molecular profiling studies. Curr Issues Mol Biol 2003, 5(2):27-35.
18. Medeiros F., Rigl C.T., Anderson G.G., Becker S.H., Halling K.C. Tissue handling for genome-wide expression analysis: a review of the issues, evidence, and opportunities. Arch Pathol Lab Med 2007, 131(12):1805-1816.
19. Lindeman N.I., Cagle P.T., Beasley M.B., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013, 137(6):828-860.
20. Wolff A.C., Hammond M.E., Hicks D.G., et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 2014, 138(2):241-256.
21. Curry J.L., Davies M.A., Calderone T.L., Nathanson K., Prieto V.G., Gershenwald J.E. Tissue resources for clinical use and marker studies in melanoma. Methods Mol Biol 2014, 1102:679-695.
22. Brimo F., Sircar K., Chevalier S., et al. Banking of fresh-frozen prostate tissue using the alternate mirror image protocol: methods, validation, and impact on the pathological prognostic parameters in radical prostatectomy. Cell Tissue Bank 2012, 13(4):631-638.
23. Diaz Z., Aguilar-Mahecha A., Paquet E.R., et al. Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine. Mod Pathol 2013, 26(11):1413-1424.
24. Marchetti I., Iervasi G., Mazzanti C.M., et al. Detection of the BRAF(V600E) mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection: an easy tool to improve the preoperative diagnosis. Thyroid 2012, 22(3):292-298.
25. Chin L., Hahn W.C., Getz G., Meyerson M. Making sense of cancer genomic data. Genes Dev 2011, 25(6):534-555.
26. van Krieken J.H., Siebers A.G., Normanno N. European Consensus Conference for external quality assessment in molecular pathology. Ann Oncol 2013, 24(8):1958-1963.
27. Smits A.J., Kummer J.A., de Bruin P.C., et al. The estimation of tumor cell percentage for molecular testing by pathologists is not accurate. Mod Pathol 2014, 27(2):168-174.
28. Viray H., Li K., Long T.A., et al. A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells. Arch Pathol Lab Med 2013, 137(11):1545-1549.
29. Gu J., Taylor C.R. Practicing pathology in the era of big data and personalized medicine. Appl Immunohistochem Mol Morphol 2014, 22(1):1-9.
30. Moch H., Blank P.R., Dietel M., et al. Personalized cancer medicine and the future of pathology. Virchows Arch 2012, 460(1):3-8.
31. Riemann K., Adamzik M., Frauenrath S., et al. Comparison of manual and automated nucleic acid extraction from whole-blood samples. J Clin Lab Anal 2007, 21(4):244-248.
32. Wang J.H., Gouda-Vossos A., Dzamko N., Halliday G., Huang Y. DNA extraction from fresh-frozen and formalin-fixed, paraffin-embedded human brain tissue. Neurosci Bull 2013, 29(5):649-654.
33. Mathot L., Wallin M., Sjoblom T. Automated serial extraction of DNA and RNA from biobanked tissue specimens. BMC Biotechnol 2013, 13:66.
34. Buehler B., Hogrefe H.H., Scott G., et al. Rapid quantification of DNA libraries for next-generation sequencing. Methods 2010, 50(4):S15-S18.
35. Metzker M.L. Sequencing technologies-the next generation. Nat Rev Genet 2010, 11(1):31-46.
36. Klampfl T., Gisslinger H., Harutyunyan A.S., et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013, 369(25):2379-2390.
37. Nangalia J., Massie C.E., Baxter E.J., et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013, 369(25):2391-2405.
38. Williams C., Ponten F., Moberg C., et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 1999, 155(5):1467-1471.
39. Kamalakaran S., Varadan V., Janevski A., et al. Translating next generation sequencing to practice: opportunities and necessary steps. Mol Oncol 2013, 7(4):743-755.
40. Xuan J., Yu Y., Qing T., Guo L., Shi L. Next-generation sequencing in the clinic: promises and challenges. Cancer Lett 2013, 340(2):284-295.
41. Plon S.E., Eccles D.M., Easton D., et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 2008, 29(11):1282-1291.
42. Schwartz M.K. Genetic testing and the clinical laboratory improvement amendments of 1988: present and future. Clin Chem 1999, 45(5):739-745.
43. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364(26):2507-2516.
44. Anderson S., Bloom K.J., Vallera D.U., et al. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med 2012, 136(11):1385-1391.
45. Halait H., Demartin K., Shah S., et al. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn Mol Pathol 2012, 21(1):1-8.
46. McArthur G.A., Chapman P.B., Robert C., et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014, 15(3):323-332.
47. Kho A.N., Rasmussen L.V., Connolly J.J., et al. Practical challenges in integrating genomic data into the electronic health record. Genet Med 2013, 15(10):772-778.
48. Mardis E.R. The $1,000 genome, the $100,000 analysis?. Genome Med 2010, 2(11):84.
49. Goecks J., Nekrutenko A., Taylor J., Galaxy Team Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol 2010, 11(8):R86.
50. Gutman D.A., Cobb J., Somanna D., et al. Cancer Digital Slide Archive: an informatics resource to support integrated in silico analysis of TCGA pathology data. J Am Med Inform Assoc 2013, 20(6):1091-1098.
51. Kandoth C., McLellan M.D., Vandin F., et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502(7471):333-339.
52. Omberg L., Ellrott K., Yuan Y., et al. Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. Nat Genet 2013, 45(10):1121-1126.
53. Tamborero D., Gonzalez-Perez A., Perez-Llamas C., et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep 2013, 3:2650.
54. Yeh P., Chen H., Andrews J., Naser R., Pao W., Horn L. DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clin Cancer Res 2013, 19(7):1894-1901.
55. Gray S.W., Hicks-Courant K., Cronin A., Rollins B.J., Weeks J.C. Physicians[U+05F3] attitudes about multiplex tumor genomic testing. J Clin Oncol 2014, 32(13):1317-1323.
56. Hofman K.J., Tambor E.S., Chase G.A., Geller G., Faden R.R., Holtzman N.A. Physicians[U+05F3] knowledge of genetics and genetic tests. Acad Med 1993, 68(8):625-632.
57. Hunter A., Wright P., Cappelli M., Kasaboski A., Surh L. Physician knowledge and attitudes towards molecular genetic (DNA) testing of their patients. Clin Genet 1998, 53(6):447-455.
58. Schwaederle M., Parker B.A., Schwab R.B., et al. Molecular tumor board: the University of California San Diego Moores Cancer Center experience. Oncologist 2014, 19(6):631-636.
59. Del Monte U. Does the cell number 10(9) still really fit one gram of tumor tissue?. Cell Cycle 2009, 8(3):505-506.